0001171000-17-000039.txt : 20170705 0001171000-17-000039.hdr.sgml : 20170705 20170705121123 ACCESSION NUMBER: 0001171000-17-000039 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170701 FILED AS OF DATE: 20170705 DATE AS OF CHANGE: 20170705 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Heffernan Mark CENTRAL INDEX KEY: 0001632439 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 17946838 MAIL ADDRESS: STREET 1: C/O NEXVET BIOPHARMA PLC STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK STATE: L2 ZIP: 00000 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2017-07-01 0001618561 Nexvet Biopharma plc NVET 0001632439 Heffernan Mark C/O NEXVET BIOPHARMA PLC UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD TULLAMORE L2 R35 FR98 IRELAND 0 1 0 0 Chief Executive Officer Ordinary Shares 2017-07-01 4 M 0 25000 .125 A 74167 D Ordinary Shares 2017-07-01 4 M 0 35643 .125 A 109810 D Ordinary Shares 243587 I By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C> Restricted Share Units .125 2017-07-01 4 M 0 25000 0 D 2017-07-01 2020-07-01 Ordinary Shares 25000 50000 D Restricted Share Units .125 2017-07-01 4 M 0 35643 0 D 2017-07-01 2020-07-01 Ordinary Shares 35643 106929 D The reporting person and his spouse share voting and dispositive power with respect to these reported securities. 25,000 of the Restricted Share Units vested and became convertible on 7/1/17 and 25,000 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting. 35,643 of the Restricted Share Units vested and became convertible on 7/1/17 and 35,643 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting. /s/ Mark Heffernan by Geraldine T. Farrell, Attorney-in-Fact 2017-07-03